BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Centene Corporation Announces 2014 Financial Guidance And Updates 2013 Financial Guidance


12/13/2013 8:26:29 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

ST. LOUIS, Dec. 13, 2013 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today its 2014 financial guidance. Premium and service revenues are expected to be $13.5 billion to $14.0 billion, representing growth of 29%. Earnings per diluted share are expected to be $3.50 to $3.80, representing an increase of 29% compared to the updated 2013 guidance range of $2.81 to $2.87.

The Company anticipates its Kentucky operations will be classified as a discontinued operation in 2014. Accordingly, all information presented and included in this release for 2014 is from continuing operations and excludes our Kentucky business. We continue to discuss the Affordable Care Act insurer fee with our State customers. While we expect to be reimbursed for the fee, including any tax consequences, we have excluded the fee from our 2014 guidance numbers to allow better comparison between years. The 2014 guidance below also does not include the impact of the recently announced acquisition of a majority interest in U.S. Medical Management, LLC, expected to close in the first quarter of 2014.

For its 2014 fiscal year, the Company expects the following results from continuing operations:

  • Premium and service revenues in the range of $13.5 billion to $14.0 billion.
  • Earnings per diluted share of approximately $3.50 to $3.80.
  • Consolidated Health Benefits Ratio of approximately 88.5% to 89.0%.
  • Consolidated G&A expense ratio in the range of 8.3% to 8.8%.
  • Effective tax rate, excluding non-controlling interest, of approximately 40% to 41%.
  • Diluted shares outstanding of approximately 57.5 million to 58.0 million.
  • Days in claims payable between 37 and 42.

The Company affirms its 2013 revenue guidance in the previously announced range for premium and service revenues of $10.6 billion to $10.8 billion and adjusts its guidance for earnings per diluted share to $2.81 to $2.87. Full year 2013 earnings will be reported on February 4, 2014, at 6:00 AM, with a conference call at 8:30 AM (Eastern Time).

Centene Corporation will host an investor meeting today, including a question-and-answer session, to discuss the details of its guidance. The meeting will begin promptly at 8:30 AM (Eastern Time) and end at approximately 11:00 AM (Eastern Time). Michael F. Neidorff, Chairman and Chief Executive Officer, and William N. Scheffel, Executive Vice President, Chief Financial Officer and Treasurer, of Centene Corporation will host the meeting before an audience of investors at the Convene conference center, 730 Third Avenue, in New York City.

Investors and other interested parties who are unable to attend in person are invited to listen to the investor meeting via a live, audio webcast on the Company's website at www.centene.com, under the Investors section.

About Centene Corporation

Centene Corporation, a Fortune 500 company, is a leading multi-line healthcare enterprise that provides programs and related services to the rising number of under-insured and uninsured individuals. Many receive benefits provided under Medicaid, including the State Children's Health Insurance Program (CHIP), as well as Aged, Blind or Disabled (ABD), Foster Care and Long-term Care (LTC), in addition to other state-sponsored/hybrid programs, and Medicare (Special Needs Plans). The Company operates local health plans and offers a range of health insurance solutions. It also contracts with other healthcare and commercial organizations to provide specialty services including behavioral health, care management software, correctional systems healthcare, life and health management, managed vision, pharmacy benefits management, specialty pharmacy and telehealth services.

The information provided in this press release contains forward-looking statements that relate to future events and future financial performance of Centene. Subsequent events and developments may cause the Company's estimates to change. The Company disclaims any obligation to update this forward-looking financial information in the future. Readers are cautioned that matters subject to forward-looking statements involve known and unknown risks and uncertainties, including economic, regulatory, competitive and other factors that may cause Centene's or its industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Actual results may differ from projections or estimates due to a variety of important factors, including Centene's ability to accurately predict and effectively manage health benefits and other operating expenses and reserves, competition, membership and revenue projections, timing of regulatory contract approval, changes in healthcare practices, changes in federal or state laws or regulations, changes in expected contract start dates, inflation, provider and state contract changes, new technologies, reduction in provider payments by governmental payors, major epidemics, disasters and numerous other factors affecting the delivery and cost of healthcare, as well as those factors disclosed in the Company's publicly filed documents. The expiration, cancellation or suspension of Centene's Medicaid Managed Care contracts, or the loss of any appeal of or protest to any such expiration, cancellation or suspension, by state governments would also negatively affect Centene.

SOURCE Centene Corporation



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES